Bricanyl contains terbutaline, a fast-onset but short-acting (4-6 hours) ß2-agonist that has been widely used since its introduction in 1970. Terbutaline acts within a few minutes of being inhaled, and is indicated for the as needed treatment of bronchial asthma, as well as for other lung diseases where bronchospasm is a complicating factor, such as chronic bronchitis and emphysema.
The as needed use of inhaled terbutaline as a reliever for asthma is well established in national and international guidelines.
Please note: This website is for an international audience of respiratory health professionals. If you are in the US you should visit MySymbicort. If you are in the UK you should visit AstraZeneca UK. If you are a patient or carer please visit My Symbicort Medicine. Not all products are available in all countries. Product licenses differ between countries. Please consult your local prescribing information.
